Glaxo Venture's Lofty Goal in HIV: Eclipse Gilead as Top Player

GlaxoSmithKline Plc’s HIV venture wants to use less burdensome forms of treatment to unseat rival Gilead Sciences Inc. and become the top player in the $26 billion-a-year market in the mid-2020s. “If our pipeline and our competitors’ pipelines play out as we’re expecting, that’s our aim,” Deborah Waterhouse, chief executive officer of ViiV Healthcare, told journalists at a briefing Wednesday in London. Glaxo and partner Pfizer Inc. are taking on Gilead with a strategy to develop two-drug HIV combinations rather than the three-drug regimens that have been the standard for many years.